Intech Biopharm Corporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 14.05 million compared to TWD 3.56 million a year ago. Net loss was TWD 71.71 million compared to TWD 65.57 million a year ago. Basic loss per share from continuing operations was TWD 0.71 compared to TWD 0.65 a year ago. Diluted loss per share from continuing operations was TWD 0.71 compared to TWD 0.65 a year ago. Basic loss per share was TWD 0.71 compared to TWD 0.65 a year ago. Diluted loss per share was TWD 0.71 compared to TWD 0.65 a year ago. For the nine months, sales was TWD 25.37 million compared to TWD 15.33 million a year ago. Net loss was TWD 221.89 million compared to TWD 185.17 million a year ago. Basic loss per share from continuing operations was TWD 2.21 compared to TWD 1.85 a year ago. Diluted loss per share from continuing operations was TWD 2.21 compared to TWD 1.85 a year ago. Basic loss per share was TWD 2.21 compared to TWD 1.85 a year ago. Diluted loss per share was TWD 2.21 compared to TWD 1.85 a year ago.